Medical Pharmacology Question Bank

Chapter 2: Pharmacokinetics — Module 1: Membrane Transport, Absorption, and Bioavailability
Tier: Tier 3 — Clinical Vignettes

1. A 42-year-old woman is brought to the emergency department after ingesting a large quantity of aspirin (acetylsalicylic acid, pKa 3.5) in a self-harm attempt. Her serum salicylate level is 620 mg/L (toxic range >300 mg/L). Her arterial blood gas shows: pH 7.28, bicarbonate 14 mEq/L (metabolic acidosis from salicylate uncoupling of oxidative phosphorylation and lactic acidosis). The emergency physician initiates intravenous sodium bicarbonate infusion and targets a urinary pH of 7.5–8.0. A medical student asks why alkalinizing the urine increases salicylate renal excretion. Which of the following best explains the pharmacokinetic mechanism?

A) Alkaline urine increases the glomerular filtration rate by reducing renal vascular resistance, increasing the filtered load of salicylate and accelerating its excretion regardless of ionization state
B) Alkaline urine converts salicylate from its ionized form to its unionized form, allowing passive reabsorption from the tubular lumen — urinary alkalinization paradoxically reduces excretion by trapping drug in the reabsorbed unionized form
C) At urinary pH 7.5–8.0, using the Henderson-Hasselbalch equation: log([ionized]/[unionized]) = pH − pKa = 7.5 − 3.5 = 4.0, so [ionized]/[unionized] = 10,000:1 — salicylate exists overwhelmingly in the ionized (deprotonated) form in alkaline urine; the charged anion cannot passively diffuse back across the lipid bilayer of the tubular epithelium, so tubular reabsorption is prevented and urinary salicylate excretion is dramatically enhanced — this is the principle of ion trapping; simultaneously, systemic bicarbonate raises blood pH, which also increases the ionized plasma fraction, distributing salicylate from tissues (including CNS) back into the more alkaline blood and reducing tissue toxicity
D) Sodium bicarbonate directly inhibits the organic anion transporter (OAT3) responsible for tubular reabsorption of salicylate — urinary alkalinization prevents OAT3-mediated salvage of salicylate from the tubular lumen back into the peritubular circulation
E) Alkaline urine increases salicylate excretion by activating ATP-dependent tubular secretion transporters (OAT1/OAT3 on the basolateral membrane) that pump salicylate from the peritubular circulation into the tubular lumen — the mechanism is active secretion enhancement, not passive ionization

ANSWER: C

Rationale:

Urinary alkalinization for salicylate poisoning is the definitive clinical application of the Henderson-Hasselbalch ion trapping principle. Salicylic acid (pKa 3.5) is the active toxic species. Applying H-H to the renal tubule: at normal urinary pH 5.0, log([A]/[HA]) = 5.0 − 3.5 = 1.5, [A]/[HA] = 31.6 — salicylate is predominantly ionized (32:1 ratio) at normal urinary pH, and some passive reabsorption of the minor unionized fraction still occurs. At alkaline urinary pH 7.5, log([A]/[HA]) = 7.5 − 3.5 = 4.0, [A]/[HA] = 10,000 — the ionized fraction increases 300-fold, reducing the reabsorbable unionized fraction to 0.01% of total tubular salicylate. This near-complete ionization in alkaline urine eliminates passive tubular reabsorption, because only the unionized form can cross the lipid bilayer of tubular epithelial cells by passive transcellular diffusion. The ionized salicylate anion is trapped within the tubular lumen and excreted in urine. Simultaneously, IV sodium bicarbonate raises systemic blood pH, which via the same H-H equilibrium increases the ionized fraction of salicylate in all body compartments — this is clinically critical because it drives salicylate from the CNS (where it causes central respiratory stimulation and later depression) and other tissues back into the bloodstream, reducing tissue toxicity. This approach can increase salicylate renal clearance 3- to 5-fold. The same principle is used for urinary alkalinization in phenobarbital poisoning (pKa 7.3 — partial ionization trapping at pH 8.0) and for urinary acidification to trap basic drugs (though urinary acidification is rarely used clinically due to risks). Option A is incorrect — bicarbonate does not meaningfully increase GFR; the mechanism is ionization-based, not hemodynamic. Option B inverts the H-H relationship for weak acids — alkaline urine increases, not decreases, ionization of a weak acid, preventing reabsorption; unionized forms are reabsorbed, not ionized forms. Option D is incorrect — OAT3 mediates tubular secretion (basolateral uptake from blood into tubular cell and apical secretion into lumen), not reabsorption; and bicarbonate's mechanism is ionization-based, not OAT3 inhibition. Option E is incorrect — the mechanism is passive (ionization-dependent prevention of reabsorption), not active secretion enhancement; OAT1/OAT3 activity is not altered by urinary pH changes.

2. A 55-year-old man with HIV infection is started on an antiretroviral regimen containing tenofovir alafenamide (TAF) and cobicistat. TAF is a prodrug that is a substrate of intestinal P-glycoprotein (P-gp). Cobicistat is a pharmacokinetic enhancer with potent P-gp inhibitory activity (in addition to CYP3A4 inhibition). The prescribing physician notes that TAF's oral bioavailability increases approximately 2.7-fold when co-administered with cobicistat compared to TAF alone. Six months later, the patient develops a respiratory infection and is prescribed rifampicin by his general practitioner, who is unaware of the antiretroviral regimen. Rifampicin is a potent inducer of both CYP3A4 and P-gp via pregnane X receptor (PXR) activation. Which of the following best predicts the pharmacokinetic consequence of adding rifampicin to this patient's regimen, and explains the clinical urgency?

A) Rifampicin will further increase TAF bioavailability by synergistically inhibiting P-gp alongside cobicistat — the combined P-gp inhibitory effect of two agents will produce supratherapeutic TAF plasma concentrations and severe nephrotoxicity
B) Rifampicin's PXR-mediated induction of P-gp and CYP3A4 will counteract cobicistat's inhibitory effects on these proteins — the net pharmacokinetic effect is neutral and no change in TAF plasma concentrations is expected; rifampicin can be safely co-administered
C) Rifampicin is a potent inducer of intestinal and hepatic P-gp and CYP3A4 via PXR activation — induction will dramatically increase P-gp efflux of TAF from enterocytes back into the gut lumen and accelerate CYP3A4-mediated intestinal and hepatic metabolism; this will reduce TAF bioavailability to levels far below what cobicistat's inhibition had achieved, potentially to sub-therapeutic concentrations insufficient to suppress HIV replication — this interaction risks virological failure, selection of antiretroviral resistance mutations, and clinical HIV disease progression; rifampicin is contraindicated with cobicistat-boosted regimens and must be substituted with rifabutin (a weaker PXR inducer with less impact on P-gp and CYP3A4) or alternative TB therapy after specialist review
D) The interaction between rifampicin and cobicistat is exclusively pharmacodynamic — rifampicin competes with cobicistat for binding to the PXR nuclear receptor, preventing cobicistat from activating PXR and thereby reducing rifampicin's own induction capacity; the net effect is reduced rifampicin efficacy against tuberculosis with no change in TAF pharmacokinetics
E) Rifampicin will decrease TAF plasma concentrations modestly (approximately 20%) by inducing hepatic CYP3A4, but because TAF itself is administered intracellularly as a prodrug, plasma TAF concentrations are an unreliable marker of efficacy and the modest plasma reduction has no clinical significance for HIV suppression

ANSWER: C

Rationale:

This case illustrates one of the most dangerous drug-drug interactions in clinical HIV pharmacology — the combination of a CYP3A4/P-gp inducer (rifampicin) with a cobicistat-boosted antiretroviral regimen. The pharmacokinetic mechanism operates on multiple levels: cobicistat boosts TAF bioavailability primarily through P-gp inhibition at the intestinal epithelium (preventing TAF efflux back into the gut lumen) and CYP3A4 inhibition (preventing intestinal first-pass metabolism). This 2.7-fold increase in TAF exposure is the designed pharmacokinetic enhancement that allows lower TAF doses to achieve therapeutic intracellular tenofovir diphosphate (TFV-DP) concentrations in lymphocytes. Rifampicin via PXR/CAR activation powerfully upregulates P-gp (ABCB1) expression in intestinal epithelium and hepatocytes, and induces CYP3A4, 2C9, 2C19, and multiple Phase II enzymes. When rifampicin's induction overwhelms cobicistat's inhibitory capacity — which it does, because cobicistat is a competitive/mechanism-based inhibitor that cannot prevent transcriptional upregulation of new P-gp and CYP3A4 protein synthesis — net P-gp activity increases and net CYP3A4 activity increases beyond baseline. This reduces TAF bioavailability to potentially sub-therapeutic levels, leading to viral load rebound, accumulation of antiretroviral resistance mutations (in TAF's tenofovir component and in companion drugs), and clinical HIV disease progression. This interaction is classified as contraindicated by all major HIV treatment guidelines (WHO, DHHS, EACS). For patients requiring concurrent TB and HIV treatment, options include: substituting rifampicin with rifabutin (rifabutin is a weaker PXR inducer, producing approximately 75% less CYP3A4 induction than rifampicin) with dose adjustment of cobicistat-boosted regimens; switching to a pharmacokinetically unboosted regimen (e.g., dolutegravir-based) that is compatible with rifampicin; or consulting an HIV/TB specialist for individualized management. Option A is incorrect — rifampicin induces, not inhibits, P-gp; its effect opposes cobicistat's inhibitory effect rather than amplifying it. Option B is incorrect — rifampicin's PXR-mediated induction of new P-gp and CYP3A4 protein synthesis cannot be blocked by cobicistat's enzyme inhibition; induction and inhibition operate through different molecular mechanisms (gene transcription vs enzyme active site competition), and induction overcomes cobicistat's inhibitory effect. Option D is incorrect — cobicistat is not a PXR activator; it is a CYP3A4/P-gp inhibitor with no meaningful effect on rifampicin's PXR-mediated induction capacity; the interaction is pharmacokinetic, not a pharmacodynamic competition at PXR. Option E is incorrect — while TAF's intracellular prodrug activation is the pharmacologically relevant step, plasma TAF concentrations correlate with intracellular TFV-DP concentrations in lymphocytes; severe reductions in plasma TAF (from enzyme induction) do translate into sub-therapeutic intracellular concentrations and virological failure risk.

3. A 31-year-old woman at 10 weeks gestation presents for prenatal pharmacology counseling. She has epilepsy managed with lamotrigine 200 mg twice daily (stable for two years, seizure-free for 18 months). Her neurologist informs her that lamotrigine plasma concentrations typically fall by 40–65% during pregnancy, often requiring dose escalation to maintain seizure control. Lamotrigine is primarily eliminated by hepatic glucuronidation via UGT1A4, and its renal clearance is approximately 10% of total clearance. Which of the following best explains the pharmacokinetic mechanism of pregnancy-related lamotrigine concentration decline?

A) Pregnancy reduces lamotrigine oral bioavailability through progesterone-mediated downregulation of intestinal absorption transporters — the lower plasma concentrations reflect reduced absorption from the GI tract rather than altered elimination
B) Pregnancy increases the apparent volume of distribution of lamotrigine through expansion of plasma volume and increased total body water — the same dose distributes into a larger volume, reducing plasma concentration without any change in elimination; dose escalation corrects for the dilutional effect by restoring the steady-state concentration
C) Pregnancy-induced elevation of estrogen and progesterone activates UGT1A4 through nuclear receptor-mediated transcriptional upregulation — increased UGT1A4 activity accelerates glucuronidation of lamotrigine to its inactive glucuronide metabolite, increasing total body clearance (CL) and reducing steady-state plasma concentration; since Css = Dose rate / CL, an increased CL at constant dose rate produces lower Css; the magnitude of UGT1A4 induction (40–65% reduction in Css) begins in the first trimester, peaks in the third trimester, and reverses within weeks postpartum — requiring prompt dose reduction after delivery to prevent lamotrigine toxicity as UGT1A4 activity normalizes
D) Pregnancy reduces lamotrigine plasma concentrations through fetal pharmacokinetic sequestration — lamotrigine crosses the placenta and distributes into the fetal compartment, producing a very large apparent volume of distribution that dilutes maternal plasma concentrations; this is a distributional, not an eliminatory, mechanism
E) The lamotrigine concentration decline during pregnancy is caused by reduced renal clearance due to the physiological increase in GFR during pregnancy — since 10% of lamotrigine clearance is renal, and GFR increases by 50% in pregnancy, total clearance increases substantially and plasma concentrations fall; dose escalation corrects for this GFR-driven clearance increase

ANSWER: C

Rationale:

Pregnancy-induced pharmacokinetic changes represent a clinically critical but frequently underappreciated area of prescribing — particularly for antiepileptic drugs where loss of seizure control carries serious risks for both mother and fetus. Lamotrigine's pregnancy pharmacokinetics are dominated by the induction of UGT1A4, its primary glucuronidation enzyme. During pregnancy, the marked elevation of estrogens (estradiol, estriol) and progesterone activates nuclear receptors — principally the aryl hydrocarbon receptor (AhR) and constitutive androstane receptor (CAR) — that transcriptionally upregulate UGT1A4 expression in the liver. This is conceptually similar to drug-induced enzyme induction (rifampicin via PXR) but driven by endogenous hormones. Increased UGT1A4 activity accelerates the glucuronidation of lamotrigine to lamotrigine-N²-glucuronide (the primary inactive metabolite), increasing total body clearance. By the relationship Css = Dose rate / CL: if CL increases by 2-fold at constant dose rate, Css falls to 50% of pre-pregnancy levels. The induction begins in the first trimester, increases through the second and third trimesters as hormone concentrations peak, and reverses rapidly postpartum as estrogen and progesterone levels fall within days of delivery. This postpartum reversal is pharmacokinetically dangerous: if doses have been escalated during pregnancy (e.g., from 200 mg to 400 mg twice daily) and are not promptly reduced after delivery, UGT1A4 returns to baseline activity within 2–3 weeks, lamotrigine CL falls back to pre-pregnancy levels, and accumulated doses produce supratherapeutic plasma concentrations with toxicity risk (dizziness, diplopia, ataxia, skin rash). The clinical management protocol therefore requires: frequent lamotrigine level monitoring during pregnancy (every 4–8 weeks), proactive dose escalation to maintain pre-pregnancy plasma concentrations, and a planned postpartum dose reduction schedule with close monitoring. Option A is incorrect — lamotrigine's intestinal absorption is not meaningfully affected by pregnancy hormones; lamotrigine has high oral bioavailability (~98%) that is maintained throughout pregnancy; the concentration decline is an elimination, not absorption, phenomenon. Option B is partially correct in noting that Vd increases during pregnancy (plasma volume expansion of approximately 40–50%, total body water increase), but the Vd change alone cannot explain a 40–65% reduction in Css; the dominant mechanism is CL increase from UGT1A4 induction, not Vd expansion. Option D is incorrect — placental transfer and fetal sequestration modestly increase apparent Vd, but the primary mechanism is hepatic UGT1A4 induction increasing CL; fetal compartment volumes are too small to produce a 40–65% reduction in maternal Css. Option E contains a fundamental pharmacokinetic error: since only 10% of lamotrigine's clearance is renal, even a 50% increase in renal clearance (GFR increase) would increase total CL by only 5% (10% × 50% = 5% increase in total CL) — utterly insufficient to explain a 40–65% Css reduction; the UGT1A4 induction of the dominant hepatic pathway (90% of CL) is the mechanistic explanation.

4. A 68-year-old man with heart failure (LVEF 30%) and atrial fibrillation is maintained on digoxin 0.125 mg daily. His renal function is stable at eGFR 55 mL/min/1.73m². He develops herpes zoster and his dermatologist prescribes clarithromycin 500 mg twice daily for a concurrent upper respiratory infection. Three days later, the patient is admitted with nausea, yellow-green visual halos, and a pulse of 44 beats per minute. His digoxin level is 3.8 ng/mL (therapeutic range 0.5–2.0 ng/mL for rate control). Which of the following best explains the complete pharmacokinetic mechanism responsible for the digoxin toxicity in this patient?

A) Clarithromycin inhibits CYP3A4, reducing hepatic metabolism of digoxin — since digoxin is primarily eliminated by CYP3A4-mediated oxidation in the liver, CYP3A4 inhibition markedly reduces digoxin clearance and causes accumulation to toxic concentrations
B) Clarithromycin is a potent inhibitor of intestinal and renal P-glycoprotein — in the intestine, P-gp inhibition increases digoxin oral bioavailability by reducing efflux of absorbed digoxin back into the gut lumen; in the kidney, P-gp inhibition reduces renal tubular secretion of digoxin (which normally accounts for a significant fraction of digoxin renal clearance beyond glomerular filtration), reducing total renal clearance; the combined increase in oral bioavailability and reduction in renal elimination produces a substantial increase in digoxin plasma concentrations — a pharmacokinetic interaction driven by P-gp inhibition at two anatomical sites, not by CYP metabolism (digoxin undergoes minimal hepatic CYP metabolism)
C) Clarithromycin causes pharmacodynamic sensitization of cardiac Na/K-ATPase to digoxin inhibition — the antibiotic modifies the ATPase enzyme's conformational state, increasing digoxin binding affinity; plasma digoxin concentration rises because more drug is released from tissue binding sites by the displaced Na/K-ATPase back into the circulation
D) Clarithromycin eradicates Eggerthella lenta — the gut bacterium responsible for metabolizing digoxin to its active form dihydrodigoxin; without this bacterial activation, digoxin accumulates as an inactive precursor that is not renally eliminated at the normal rate, causing plasma accumulation without pharmacological effect
E) The digoxin toxicity results from a pharmacokinetic interaction at the level of plasma protein binding — clarithromycin displaces digoxin from albumin binding sites, increasing free digoxin fraction and producing toxicity at a total plasma concentration that was previously sub-toxic; the total plasma digoxin level of 3.8 ng/mL reflects the displaced free fraction and overestimates the actual pharmacologically active concentration

ANSWER: B

Rationale:

The digoxin-clarithromycin interaction is one of the most clinically well-characterized and pharmacokinetically instructive P-glycoprotein drug interactions in clinical medicine. Understanding why this interaction is driven by P-gp rather than CYP metabolism requires knowledge of digoxin's unique pharmacokinetic profile. Digoxin undergoes negligible hepatic CYP-mediated metabolism (less than 10% of elimination), making it an atypical drug whose disposition is predominantly governed by transporters and renal elimination: approximately 70% of digoxin is eliminated unchanged by the kidney through glomerular filtration and active tubular secretion, and intestinal P-gp is a major determinant of its oral bioavailability. Clarithromycin is a potent P-gp inhibitor (in addition to being a CYP3A4 inhibitor). The digoxin-clarithromycin interaction operates through P-gp inhibition at two sites: (1) Intestinal epithelium — clarithromycin inhibits apical P-gp in enterocytes, reducing the efflux of absorbed digoxin back into the gut lumen; this increases intestinal bioavailability of digoxin, delivering more drug per dose into the portal circulation; (2) Renal proximal tubular epithelium — P-gp (expressed on the apical surface of tubular cells) contributes significantly to digoxin tubular secretion; clarithromycin inhibition of renal P-gp reduces net digoxin tubular secretion, decreasing total renal clearance. The combined effect — increased intestinal absorption + decreased renal elimination — produces a 1.7- to 2.3-fold increase in digoxin AUC and trough concentrations, elevating plasma levels from therapeutic (0.125 mg producing ~0.8–1.2 ng/mL trough) to toxic (3.8 ng/mL). The clinical presentation — nausea, yellow-green visual halos (xanthopsia), and bradycardia (44 bpm from AV nodal conduction slowing) — is classic digoxin toxicity. The cardiac manifestations reflect digoxin's pharmacodynamic mechanism (Na/K-ATPase inhibition causing intracellular calcium overload and enhanced automaticity). Management: hold digoxin, continuous cardiac monitoring, electrolyte correction (especially potassium and magnesium), and digoxin-specific Fab fragment antibodies (DigiFab) for severe toxicity. Option A is incorrect — digoxin undergoes minimal CYP3A4 metabolism; CYP inhibition by clarithromycin is not the mechanism of this interaction; the mechanism is P-gp inhibition. Option C is incorrect — clarithromycin does not pharmacodynamically sensitize Na/K-ATPase to digoxin; the interaction is pharmacokinetic, not pharmacodynamic. Option D inverts the Eggerthella lenta mechanism — E. lenta reduces digoxin to the less active dihydrodigoxin (an inactivation pathway, not activation); antibiotic eradication of E. lenta would increase (not decrease) active digoxin levels by preventing inactivation — contributing a secondary pharmacokinetic mechanism in some patients. Option E is incorrect — digoxin has very low plasma protein binding (~25%); displacement from albumin is not pharmacokinetically meaningful for digoxin; moreover, elevated total digoxin of 3.8 ng/mL confirms increased drug exposure, not merely a protein binding shift.

5. A 19-year-old woman presents to her GP requesting a prescription for a combined oral contraceptive pill (OCP) containing ethinylestradiol 30 mcg and levonorgestrel 150 mcg. During the consultation she mentions she takes St. John's Wort (Hypericum perforatum, 900 mg daily) as a complementary treatment for mild depression. Her GP expresses concern about a pharmacokinetic drug interaction. Ethinylestradiol is primarily metabolized by CYP3A4 and undergoes enterohepatic recirculation; it is also a P-gp substrate. St. John's Wort contains hyperforin, a potent pregnane X receptor (PXR) activator. Which of the following best describes the complete pharmacokinetic mechanism by which St. John's Wort reduces OCP efficacy, and the most appropriate clinical management?

A) St. John's Wort inhibits CYP3A4 through direct enzyme active site binding — reduced ethinylestradiol metabolism raises plasma estrogen concentrations, producing OCP-related adverse effects (nausea, breast tenderness, thromboembolism risk) rather than contraceptive failure; the appropriate management is to switch to a lower-dose OCP formulation
B) Hyperforin activates PXR, transcriptionally inducing CYP3A4, CYP2C9, P-glycoprotein (ABCB1), and UGT enzymes in the intestinal wall and liver — CYP3A4 induction increases first-pass and systemic metabolism of ethinylestradiol and levonorgestrel, reducing their plasma concentrations; P-gp induction increases intestinal efflux, further reducing their bioavailability; UGT induction accelerates Phase II conjugation and biliary excretion, disrupting enterohepatic recirculation; the combined effect reduces ethinylestradiol and levonorgestrel plasma concentrations by 40–60%, potentially below the threshold for reliable ovulation suppression — this is a well-documented cause of OCP failure and unintended pregnancy; the appropriate management is to discontinue St. John's Wort and use an alternative antidepressant or non-hormonal contraception; if the OCP is continued, an additional barrier method is required for at least four weeks after St. John's Wort discontinuation as enzyme induction resolves
C) St. John's Wort reduces OCP efficacy through a pharmacodynamic mechanism — hyperforin competes with ethinylestradiol for estrogen receptor binding in the hypothalamus, preventing the negative feedback inhibition of gonadotropin-releasing hormone that underlies OCP contraceptive efficacy; the mechanism is receptor competition, not altered pharmacokinetics
D) The interaction between St. John's Wort and OCPs is clinically negligible — hyperforin activates PXR at doses far above what is consumed in commercial St. John's Wort preparations (900 mg), and no clinically significant change in ethinylestradiol plasma concentrations has been documented in clinical studies; the GP's concern is based on theoretical, not demonstrated, pharmacokinetics
E) St. John's Wort reduces OCP efficacy solely by disrupting enterohepatic recirculation — hyperforin inhibits intestinal -glucuronidase enzymes responsible for deconjugating the ethinylestradiol glucuronide secreted in bile, preventing estrogen reabsorption; since enterohepatic recirculation accounts for 100% of ethinylestradiol's active plasma concentration, complete disruption of this mechanism eliminates all pharmacological effect

ANSWER: B

Rationale:

The St. John's Wort–oral contraceptive interaction is one of the most clinically important and pharmacokinetically comprehensive herbal drug interactions, with documented unintended pregnancies and therapeutic failures across multiple drug classes. Hyperforin — the primary pharmacokinetically active component of St. John's Wort — is a potent ligand and activator of the pregnane X receptor (PXR), a nuclear receptor that functions as a master transcriptional regulator of drug-metabolizing enzyme and transporter gene expression. PXR activation by hyperforin transcriptionally upregulates multiple proteins: CYP3A4 (major metabolic enzyme for ethinylestradiol and levonorgestrel) — producing increased intestinal and hepatic first-pass metabolism; CYP2C9 — contributing to levonorgestrel metabolism; P-glycoprotein (ABCB1) — producing increased intestinal efflux of drug back into the gut lumen, reducing absorption; UGT enzymes — accelerating Phase II glucuronidation and biliary excretion. Additionally, the acceleration of Phase II metabolism produces more conjugated metabolite for biliary secretion, but enhanced UGT activity also conjugates newly deconjugated (recycled) drug more rapidly — effectively shortening the enterohepatic recirculation cycle. The combined pharmacokinetic effect reduces ethinylestradiol plasma AUC by 40–60% and levonorgestrel AUC by approximately 30–40% in women taking St. John's Wort 900 mg daily — concentrations that may fall below the threshold for reliable suppression of the hypothalamic-pituitary-ovarian axis (LH and FSH suppression, anovulation). Multiple case reports of OCP failure, breakthrough bleeding (early sign of inadequate ovarian suppression), and unintended pregnancy have been documented. The enzyme induction persists for 2–4 weeks after St. John's Wort discontinuation (the time required for new CYP3A4 and P-gp protein synthesis to replace induced enzyme that is gradually degraded at baseline turnover rates) — requiring continued additional contraceptive precautions during this period. Option A inverts the interaction direction — St. John's Wort is an inducer, not an inhibitor, of CYP3A4; it reduces, not increases, ethinylestradiol concentrations. Option C describes a pharmacodynamic mechanism that does not exist — hyperforin does not compete with estradiol for estrogen receptor binding; the mechanism is entirely pharmacokinetic. Option D is incorrect — multiple human clinical pharmacokinetic studies have documented significant reductions in ethinylestradiol and levonorgestrel plasma concentrations with St. John's Wort 900 mg daily; the interaction is well-established, not merely theoretical. Option E is incorrect — while EHR disruption contributes to the interaction, it is not the sole mechanism and EHR does not account for 100% of ethinylestradiol's plasma concentration; the primary mechanisms are CYP3A4 induction of first-pass and systemic metabolism and P-gp induction reducing bioavailability.

6. A 44-year-old man with a 25-year history of alcohol use disorder presents with a five-day history of worsening abdominal pain, nausea, and jaundice. Laboratory results reveal: ALT 2,450 IU/L, AST 1,820 IU/L, bilirubin 145 µmol/L, INR 2.8, serum albumin 22 g/L, and an eGFR of 38 mL/min/1.73m². He is Child-Pugh Class C. He requires pain management. The inpatient team considers oral morphine. Morphine is a high-extraction drug (ER 0.75) that is primarily eliminated by hepatic glucuronidation (UGT2B7) to morphine-6-glucuronide (M6G, active analgesic) and morphine-3-glucuronide (M3G, neuroexcitatory, inactive analgesic), with approximately 10% renal elimination of parent drug. Which of the following best predicts the complete pharmacokinetic profile of oral morphine in this patient and the most appropriate prescribing decision?

A) Morphine's pharmacokinetics will be unaffected by this patient's liver disease because glucuronidation (Phase II metabolism) is preserved in hepatic failure — only CYP-mediated Phase I reactions are impaired in liver disease; morphine can be prescribed at standard oral doses without modification
B) The patient's Child-Pugh C status will reduce morphine oral bioavailability because severe hepatic failure impairs GI absorption of opioids — lower bioavailability means higher oral doses are required to achieve adequate analgesia; oral morphine should be dosed at 2-fold the standard dose to compensate for malabsorption
C) He requires pain management. The inpatient team considers oral morphine. Morphine is a high-extraction drug (ER 0.75) that is primarily eliminated by hepatic glucuronidation (UGT2B7) to morphine-6-glucuronide (M6G, active analgesic) and morphine-3-glucuronide (M3G, neuroexcitatory, inactive analgesic), with approximately 10% renal elimination of parent drug. Which of the following best predicts the complete pharmacokinetic profile of oral morphine in this patient and the most appropriate prescribing decision? A. Morphine's pharmacokinetics will be unaffected by this patient's liver disease because glucuronidation (Phase II metabolism) is preserved in hepatic failure — only CYP-mediated Phase I reactions are impaired in liver disease; morphine can be prescribed at standard oral doses without modification B. The patient's Child-Pugh C status will reduce morphine oral bioavailability because severe hepatic failure impairs GI absorption of opioids — lower bioavailability means higher oral doses are required to achieve adequate analgesia; oral morphine should be dosed at 2-fold the standard dose to compensate for malabsorption C. In Child-Pugh C hepatic cirrhosis: (1) reduced hepatic blood flow and functional hepatocyte mass reduce morphine's hepatic extraction ratio, dramatically increasing oral bioavailability (from approximately 25% in healthy adults to potentially 60–80% or more); (2) reduced UGT2B7 activity impairs glucuronidation of morphine, reducing formation of M6G (active) and M3G, and prolonging morphine half-life; (3) hypoalbuminemia (albumin 22 g/L) increases the unbound fraction of morphine, increasing distribution and CNS penetration; (4) reduced eGFR impairs clearance of renally excreted M6G, causing accumulation of this active metabolite and prolonging and intensifying analgesia; (5) the net effect is dramatically increased and prolonged morphine exposure at standard doses with high risk of respiratory depression, sedation, and opioid toxicity; oral morphine should be used only at substantially reduced doses and intervals with close respiratory monitoring, or a non-hepatically-metabolized alternative should be selected
D) The reduced eGFR of 38 mL/min/1.73m² is the only relevant pharmacokinetic alteration — because morphine is primarily hepatically metabolized, the Child-Pugh C status has no impact on morphine pharmacokinetics; the only dose adjustment required is a 30% reduction for mild renal impairment
E) Oral morphine is absolutely contraindicated in all patients with Child-Pugh Class C disease — international pharmacovigilance data establish that opioids uniformly cause irreversible hepatic failure in Child-Pugh Class C patients through direct hepatotoxic mechanisms, and no analgesic dose adjustment can make their use safe

ANSWER: C

Rationale:

This case requires integrating multiple simultaneous pharmacokinetic alterations in a patient with severe hepatic impairment and mild-moderate renal impairment — a clinically challenging scenario that demands systematic pharmacological reasoning. The complete pharmacokinetic consequence of Child-Pugh C cirrhosis for oral morphine is multifactorial and converging toward dramatically increased drug exposure: (1) Bioavailability increase — morphine's hepatic ER of approximately 0.75 in healthy adults means only approximately 25% reaches systemic circulation after oral dosing (F = 1 − ER = 0.25). In Child-Pugh C cirrhosis, reduced hepatic blood flow (portal hypertension, intrahepatic shunting) and massively reduced functional hepatocyte mass (reflected by ALT 2450, INR 2.8, bilirubin 145) reduce both blood flow-dependent (Q) and intrinsic clearance (CLint) components of the extraction ratio. ER falls dramatically, potentially to 0.2–0.4, increasing F from 25% to 60–80% — a 2.5 to 3-fold increase in bioavailability from an unchanged oral dose. (2) Reduced clearance — impaired UGT2B7 reduces glucuronidation of morphine to M3G and M6G, reducing total hepatic clearance and prolonging morphine's half-life. (3) Hypoalbuminemia — serum albumin 22 g/L (vs normal 35–50 g/L) increases the unbound fraction of morphine, increasing distribution volume and CNS penetration (morphine is approximately 35% protein-bound). (4) Renal impairment and M6G accumulation — while morphine itself has only 10% renal clearance, its active analgesic metabolite M6G is renally cleared; eGFR 38 mL/min/1.73m² impairs M6G elimination, causing accumulation of this potent active metabolite that contributes to analgesic effect and respiratory depression risk — particularly dangerous in a patient already receiving more morphine due to increased bioavailability and reduced clearance. The combined pharmacokinetic effect makes standard oral morphine doses profoundly dangerous in this patient. Clinical management options: dramatically reduced doses with extended intervals under close monitoring; transmucosal or IV routes in hospital with titration; or selection of an opioid with less complex pharmacokinetic alteration in liver disease (e.g., fentanyl — primarily CYP3A4, though also affected; or tramadol — with its own complex metabolism). Option A is incorrect — glucuronidation (Phase II) is significantly impaired in severe hepatic failure; the claim that only Phase I reactions are affected is incorrect; both phases are reduced when functional hepatocyte mass is severely compromised. Option B inverts the bioavailability change — hepatic failure increases, not decreases, the oral bioavailability of high-extraction drugs by reducing first-pass extraction; lower doses, not higher, are required. Option D incorrectly dismisses the hepatic pharmacokinetic impact — Child-Pugh C status is the dominant pharmacokinetic alteration here, not eGFR 38; and characterizing eGFR 38 as "mild renal impairment" is inaccurate (it represents CKD stage 3b — moderate). Option E is incorrect — opioids do not cause direct hepatotoxicity; morphine can be used in liver disease with appropriate dose modification and monitoring; absolute contraindication is not the evidence-based position.